BSEM - BioStem Technologies, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

BSEM

BIOSTEM TECHNOLOGIES, INC.

NASDAQ

$3.54

▼ DOWN 3.80% (-0.14)

KEY STATISTICS

Market Cap$60.12 M

52w High$8.40

52w Low$2.25

Dividend Yield—

Frequency—

P/E-3.37

Volume63.39K

Shares Out.16.98M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Jason Matuszewski

ABOUT

SECTOR

Healthcare

WENT PUBLIC

March 17, 2015

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

PRICE TARGET

Target High$9.00

Target Low$9.00

Target Median$9.00

Target Consensus$9.00

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.$7.96M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2015-01-29	Reverse	1:400
2013-02-01	Reverse	1:35
2008-11-28	Reverse	1:1000

PRICE

$3.54 ▼ DOWN 3.80% (−$0.14)

OVERLAYS

About BioStem Technologies, Inc.

https://biostemtechnologies.com ↗

BioStem Technologies, Inc. develops and commercializes placental-derived allografts for advanced wound care and regenerative therapies, offering products like Vendaje and American Amnion for soft tissue and ocular surface protection.

INDUSTRY

Biotechnology

A PRODUCT BIOSTEM TECHNOLOGIES, INC. IS KNOWN FOR

Neox® 1K

Neox® 1K, a cryopreserved thick human amniotic membrane allograft acquired in 2026, is now BioStem Technologies' main revenue driver, focusing on hospital and surgical wound care.